In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter ...

Emboline is one step closer to the commercialization of its Emboliner Embolic Protection System. The Santa Cruz, CA-based ...

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...

Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable ...

Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.

Background Transcatheter aortic valve replacement (TAVR) has already been recommended for some high-risk patients with aortic ...

Transcatheter aortic valve replacement with self-expanding valves was associated with significantly lower mean aortic valve ...

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

The novel findings, published today in the peer-reviewed journal The Lancet, are significant because recent randomized clinical trials have shown that TAVR is a meaningful treatment option for both ...

SAN FRANCISCO -- Better indicators of high-grade atrioventricular (AV) conduction system abnormalities following transcatheter aortic valve replacement (TAVR) could be gleaned from an intraprocedural ...

Repeat transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve is effective in treating a failed first transcatheter valve, with low procedural risks and with clinical outcomes ...